Here, we scrutinized the impact of BRAF/MEK inhibition on adaptive immune responses in melanoma patients by performing a comprehensive immunological characterization in sequential tumor biopsies obtained before and during BRAF/MEK inhibition. The gene discussed is MAP2K7; the disease is melanoma.